Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24


  • Randomized Clinical Trials for DCIS
    • Irene L. Wapnir, James J. Dignam, Bernard Fisher, Eleftherios P. Mamounas, Stewart J. Anderson, Thomas B. Julian, Stephanie R. Land, Richard G. Margolese, Sandra M. Swain, Joseph P. Costantino, Norman Wolmark
  • Background:
    • Ipsilateral breast tumor recurrence (IBTR):
      • Is the most common failure event after lumpectomy for ductal carcinoma in situ (DCIS)
    • Wapnir and colleagues evaluated invasive IBTR (I-IBTR) and its influence on survival:
      • Among participants in two National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized trials for DCIS:
        • NSABP B-17
        • NSABP B-24
  • Methods:
    • In the NSABP B-17 trial:
      • Accrual period:
        • October 1, 1985, to December 31, 1990
    • Patients with localized DCIS were randomly assigned to:
      • The lumpectomy only (LO, n = 403) group or
      • To the lumpectomy followed by radiotherapy (LRT, n = 410) group
    • In the NSABP B-24 trial:
      • Double-blinded, placebo-controlled trial
      • Accrual period:
        • May 9, 1991, to April 13, 1994
      • All accrued patients were randomly assigned to:
        • LRT+ placebo, (n=900) or
        • LRT + tamoxifen (LRT + TAM, n = 899)
    • Endpoints included:
      • I-IBTR
      • DCIS-IBTR
      • Contralateral breast cancers (CBC)
      • Over-all and breast cancer–specific survival
      • Survival after I-IBTR
    • Median follow-up was:
      • 207 months for the B-17 trial:
        • N = 813 patients
      • 163 months for the B-24 trial:
        • N = 1799 patients
  • Results:
    • Of 490 IBTR events:
      • 263 (53.7%) were invasive
    • Radiation reduced I-IBTR by:
      • 52% in the LRT group compared with LO:
        • NSABP B-17:
          • Hazard ratio [HR] of risk of I-IBTR:
            • 0.48, 95% confidence interval [CI] = 0.33 to 0.69, P < .001
        • NSAPB B-24:
          • LRT + TAM reduced I-IBTR:
            • By 32% compared with LRT + placebo:
              • HR of risk of I-IBTR:
                • 0.68, 95% CI = 0.49 to 0.95, P = .025)
    • The 15-year cumulative incidence of I-IBTR was:
      • 19.4% for LO
      • 8.9% for LRT (B-17)
      • 10.0% for LRT + placebo (B-24)
      • 8.5% for LRT + TAM
    • The 15-year cumulative incidence of all contralateral breast cancers was:
      • 10.3% for LO
      • 10.2% for LRT (B-17)
      • 10.8% for LRT + placebo (B-24)
      • 7.3% for LRT + TAM
    • I-IBTR:
      • Was associated with increased mortality risk:
        • HR of death = 1.75, 95% CI = 1.45 to 2.96, P < .001
      • Whereas recurrence of DCIS was not
      • Twenty-two of 39 deaths after I-IBTR were attributed to breast cancer
    • Among all patients (with or without I-IBTR), the 15-year cumulative incidence of breast cancer death was:
      • 3.1% for LO
      • 4.7% for LRT (B-17)
      • 2.7% for LRT + placebo (B-24)
      • 2.3% for LRT + TAM

#Arrangoiz #BreastSurgeon #CancerSurgeon #BreastCancer #Teacher #Surgeon

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s